A Novel Stroke Treatment Strategy Fails to Provide Neuroprotective Benefit

Ischemic perconditioning did not reduce brain infarct growth in patients with carotid-territory ischemic stroke.

Ischemic conditioning — the application of brief periods of transient ischemia without producing tissue necrosis — has been shown to decrease stroke infarct volumes in animal models. The procedure can be done directly to an organ (preconditioning) or to a remote area of the body (perconditioning).

Now, investigators in France have conducted a multicenter, prospective, randomized trial to assess the utility of in-hospital ischemic perconditioning (IP) in 188 patients (mean age, 67 years) with carotid-territory ischemic stroke confirmed by MRI within 6 hours of symptom onset (median NIH stroke score, 10; median brain infarction volume, 11.4 cm³).

Patients received either standard care or standard care plus IP, which entailed inflation of a bloo…

Reviewing Author

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

A Novel Stroke Treatment Strategy Fails to Provide Neuroprotective Benefit

Topics

Reviewing Author